touchEXPERT BRIEFING UCB, making a difference in immunology
Watch Drs Ronald Vender, Richard Warren and Xenofon Baraliakos discuss UCB’s contributions to the treatment of immunological disease.
Dr Ronald Vender discusses working with UCB, including specific examples of their contributions from his personal experience in Canada.
1/3 Next InterviewIn this interview, we asked Dr Ronald Vender the following questions:
- What has been your personal experience of working with UCB?
- Please outline some of the key contributions UCB has made to HCPs and patients and in immunological diseases
- How do you feel the approach of UCB differs from other companies?
- What future contributions of UCB do you anticipate in the field of immunological diseases?
Ronald Vender practices dermatology in Ontario, Canada. He is Associate Clinical Professor of Medicine at McMaster University, and is founder and director of Dermatrials Research Inc. He has conducted over 120 clinical trials enrolling over 1000 participants.
Dr Vender serves as peer reviewer for many high-impact journals, including JAAD, JEADV, and BJD. He is one of 7 Canadians elected to the International Psoriasis Council. He has been an active consultant to the pharmaceutical industry for over 25 years.
Dr Ronald Vender discloses: Grants from Abbvie, Amgen, Arcutis, Bausch, Health, Boehringer, Ingelheim, BMS, Celgene, Centocor, Dermira, Dermavant, Galderma, GlaxoSmithKline, Innovaderm, Janssen, LEO Pharma, Eli Lilly and Company, Mediji, Merck, Novartis, Pfizer, Regeneron, Sun Pharma, Takeda and USB. Consulting fees from Abbvie, Actelion, Amgen, Aralez, Arcutis, Bausch-Health, Boehringer Ingelheim, BMS, Celgene, Cipher, Janssen, Galderma, GSK, Kabo-Care, LEO Pharma, Eli Lilly and Company, Merck, Novartis, Palladin, Pfizer, Sandoz, SUN, UCB and Viatris-Mylan. Payment or honoraria for lectures or presentations from Abbvie, Actelion, Amgen, Arcutis, Bausch-Health, BMS, Celgene, Cipher, Janssen, Galderma, GSK, LEO pharma, Eli Lilly and Company, Merck, Novartis, Pfizer, Sun and UCB. Support for attending meetings or travel from Abbvie, Arcutis, Janssen and UCB.
Prof. Richard Warren discusses his personal UK-based experience of working with UCB giving specific examples of their contributions to immunological disease, patients and healthcare practitioners.
2/3 Next InterviewIn this interview, we asked Prof. Richard Warren the following questions:
- What has been your personal experience of working with UCB?
- Please outline some of the key contributions UCB has made to HCPs and patients and in immunological diseases
- How do you feel the approach of UCB differs from other companies?
- What future contributions of UCB do you anticipate in the field of immunological diseases?
Richard Warren is a consultant dermatologist in Manchester, UK.
Prof. Warren’s work in dermatology has focused on pharmacogenetics, the genetic susceptibility to psoriasis, and biologic therapies in the treatment of psoriasis. He has received national and international awards for his work into the pharmacogenetics of methotrexate. His current roles include Academic Vice President of the British Association of Dermatologists and Lead for early phase trial research across the Northern Care Alliance in Greater Manchester.
Prof. Richard Warren discloses: Grant/research support from AbbVie, Novartis, and Pfizer. Consultant for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and Xenoport. Speakers’ bureau member for AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, and Pfizer. Honoraria from UCB.
Prof. Dr Xenofon Baraliakos discusses they key past, present and future contributions of UCB to immunological diseases, patients and healthcare practitioners from his personal experience in Germany.
3/3 Leave FeedbackIn this interview, we asked Prof. Dr Xenofon Baraliakos the following questions:
- What has been your personal experience of working with UCB?
- Please outline some of the key contributions UCB has made to HCPs and patients and in immunological diseases
- How do you feel the approach of UCB differs from other companies?
- What future contributions of UCB do you anticipate in the field of immunological diseases?
Xenofon Baraliakos is Senior Consultant and Scientific Coordinator at the Rheumazentrum Ruhrgebiet in Herne, Germany, and Associate Professor of Internal Medicine and Rheumatology at the Ruhr University in Bochum, Germany.
Prof. Dr Baraliakos’ research interests include clinical and academic research in the field of spondyloarthritides, with special emphasis on imaging outcomes and treatment of the disease. He won the EWRR Award in 2005, the EULAR Young Investigator Award in 2006 and 2008, the German patient’s AS Society Award in 2010, and the 2014 Award for Excellence in Clinical Research from the European Society for Clinical Investigation (ESCI), among others.
Prof. Dr Xenofon Baraliakos discloses: Consulting for Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB. Payment or honoraria for lectures from Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB. Grant/ research support from Abbvie, Novartis and MSD. Advisory boards for Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB. Honoraria from Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB.  Speakers’ bureaus member for Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB.
Overview & Learning Objectives
Overview
UCB have made contributions to advances of several immunological diseases, including psoriasis and ankylosing spondylitis, in addition to supporting healthcare practitioners treating these diseases and their patients. In this activity, leading experts discuss specific examples of the previous, present and in-development contributions of UCB to the management of immunological diseases, healthcare practitioners treating these diseases and their patients.
Learning Objectives
After watching this activity, participants should be better able to:
- Describe the previous, present and in-development contributions of UCB to support of HCPs managing immunological diseases
- Outline the previous, present and in-development contributions of UCB to support patients with immunological diseases
- Discuss the previous, present and in-development contributions of UCB to the understanding of immunological diseases
For more information on UCB’s contributions to immunology, please visit the UCB.com microsite (external site).
Faculty & Disclosures
Dr Ronald Vender
McMaster University, Hamilton, ON, Canada
Ronald Vender practices dermatology in Ontario, Canada. He is Associate Clinical Professor of Medicine at McMaster University, and is founder and director of Dermatrials Research Inc. He has conducted over 120 clinical trials enrolling over 1000 participants.
Dr Vender serves as peer reviewer for many high-impact journals, including JAAD, JEADV, and BJD. He is one of 7 Canadians elected to the International Psoriasis Council. He has been an active consultant to the pharmaceutical industry for over 25 years.
Dr Ronald Vender discloses: Grants from Abbvie, Amgen, Arcutis, Bausch, Health, Boehringer, Ingelheim, BMS, Celgene, Centocor, Dermira, Dermavant, Galderma, GlaxoSmithKline, Innovaderm, Janssen, LEO Pharma, Eli Lilly and Company, Mediji, Merck, Novartis, Pfizer, Regeneron, Sun Pharma, Takeda and USB. Consulting fees from Abbvie, Actelion, Amgen, Aralez, Arcutis, Bausch-Health, Boehringer Ingelheim, BMS, Celgene, Cipher, Janssen, Galderma, GSK, Kabo-Care, LEO Pharma, Eli Lilly and Company, Merck, Novartis, Palladin, Pfizer, Sandoz, SUN, UCB and Viatris-Mylan. Payment or honoraria for lectures or presentations from Abbvie, Actelion, Amgen, Arcutis, Bausch-Health, BMS, Celgene, Cipher, Janssen, Galderma, GSK, LEO pharma, Eli Lilly and Company, Merck, Novartis, Pfizer, Sun and UCB. Support for attending meetings or travel from Abbvie, Arcutis, Janssen and UCB.
Prof. Richard Warren
University of Manchester, Manchester, UK
Richard Warren is a consultant dermatologist in Manchester, UK.
Prof. Warren’s work in dermatology has focused on pharmacogenetics, the genetic susceptibility to psoriasis, and biologic therapies in the treatment of psoriasis. He has received national and international awards for his work into the pharmacogenetics of methotrexate. His current roles include Academic Vice President of the British Association of Dermatologists and Lead for early phase trial research across the Northern Care Alliance in Greater Manchester.
Prof. Richard Warren discloses: Grant/research support from AbbVie, Novartis, and Pfizer. Consultant for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and Xenoport. Speakers’ bureau member for AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, and Pfizer. Honoraria from UCB.
Prof. Dr Xenofon Baraliakos
Ruhr University Bochum, Bochum, Germany
Xenofon Baraliakos is Senior Consultant and Scientific Coordinator at the Rheumazentrum Ruhrgebiet in Herne, Germany, and Associate Professor of Internal Medicine and Rheumatology at the Ruhr University in Bochum, Germany.
Prof. Dr Baraliakos’ research interests include clinical and academic research in the field of spondyloarthritides, with special emphasis on imaging outcomes and treatment of the disease. He won the EWRR Award in 2005, the EULAR Young Investigator Award in 2006 and 2008, the German patient’s AS Society Award in 2010, and the 2014 Award for Excellence in Clinical Research from the European Society for Clinical Investigation (ESCI), among others.
Prof. Dr Xenofon Baraliakos discloses: Consulting for Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB. Payment or honoraria for lectures from Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB. Grant/ research support from Abbvie, Novartis and MSD. Advisory boards for Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB. Honoraria from Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB.  Speakers’ bureaus member for Abbvie, BMS, Eli-Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB.
